BIO provides scientific advisory services to start-up and biotechnology companies focusing on drug development from preclinical to clinical validation. BIO is also an investment consulting company that assists venture capital firms, institutional investors, and banks with analyzing potential investments or portfolio records associated with a company, its present course and future plans. The Company’s broad knowledge of the market players and the latest scientific trends in the drug discovery industry joined with our hands-on management experience provides insights that may not be apparent to the usual financial investor.
BIO specializes in drug development from early preclinical research to clinical validation with twenty years of operating experience resulting in the advancement of several compounds into human clinical trials (Phase I – III). BIO provides expertise in clinical development, intellectual property, regulatory, equity financings and in-depth scientific knowledge of cancer immunotherapy, gene therapy, immunology and CNS. With our wide international network of contacts in both industry and academia, BIO can facilitate development of customer and partner relationships and help establish critical collaborations.
ADVISORY
INVESTMENT
Our investment consulting practice focuses on helping Family Offices, VCs and Institutional Investors by analyzing life science companies, their present course and future. Our broad knowledge of the market players and the latest scientific trends in the drug discovery industry joined with our hands-on management experience allow us to provide insights that may not be apparent to the usual financial investor. A sampling of our investor services includes technology analysis, competition evaluation, financial assessment, portfolio analysis, and due diligence assistance.
OUR CLIENTS
ABOUT
Federica Pericle, PhD, MBA, Managing Director of BIO has over 25 years’ experience in scientific, strategic and leadership positions within the biotechnology industry and academia. Recently she was the President and CEO of Agilvax, Inc., a biotechnology company developing novel cancer therapies and vaccines for infection diseases. She is also an experienced life science analyst advising financial institutions. Dr. Pericle is currently serving as Analyst for Bluestar Investment Managers (www.bluestar-im.ch) managing Onelife Fund fully dedicated to the life science sector (~$70MM). Prior to Agilvax she was the co-founder and COO of SeneXta Therapeutics, a clinical stage company developing treatments for CNS disorders. She was also the founder and CEO of EP Pharma, a start-up biotech company developing novel small molecules for the treatment of leukemia and lymphoma. Previously, Dr. Pericle worked as a scientific advisor for Agennix, Inc. a biopharmaceutical company focused on developing protein-based drugs for oncology and was the Director of the Oncology Program at Valentis in Houston, TX. She has also worked as a Senior Scientist at the National Cancer Institute (NCI) and has over 25 years of research experience in the fields of oncology, immunology, CNS, inflammation, antibody/protein drug development, and gene therapeutics. Dr. Pericle led the development of five product candidates into clinical trials for the treatment of cancer/CNS, published over 50 scientific articles in peer-reviewed journals and co-authored five patents in the field of cancer. She received her Ph.D. in Biological Sciences from Turin University in Italy and has a specialization in Immunology/Cancer Immunotherapy from the University of South Florida. She also holds an MBA from Texas A&M University.
